Liraglutide
Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia
Novo Nordisk · Phase 2/3 · Withdrawn · Enrollment 0
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| MA alone | n/r | n/r | n/r | n/r |
| MA+liraglutide | n/r | n/r | n/r | n/r |
Not shown
- MA alone: endpoint not reported
- MA+liraglutide: endpoint not reported